As a well-known example, evaluation of PD-L1 staining on tumour biopsies is currently used to inform clinical decision-making, but factors like intratumoural heterogeneity, interobserver variability, and sampling error can heavily influence the outcome, and PD-L1-negative patients may still respond [4,5,6,7]. The gene discussed is CD274; the disease is neoplasm.